achive.php

The Institute of Medicinal Plant Development has licensed Scilligence’s TouchMol4Office

Boston, February 14, 2017

The Institute of Medicinal Plant Development (IMPLAD) has licensed Scilligence’s TouchMol4Office, a cheminformatics and bioinformatics plug-in for Microsoft Office. This informatics tool will significantly enhance researchers’ ability to analyze and visualize chemical compositions of natural products in medicinal herbs.

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

About The Institute of Medicinal Plant Development
The Institute of Medicinal Plant Development (IMPLAD), and Beijing Medicinal Plant Garden, affiliated with the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), was established in August 1983. The headquarters are located in Zhongguancun Scientific and Technical Zone, Beijing, with six branches respectively distributed in Yunan, Hainan, Guangxi, Xinjiang, Chongqing, and Guizhou. As the only one national research institution of public service specializing in protection, development, and utilization of medicinal plant resources, and also one of the well-known institutions focusing on medicinal plant research worldwide, IMPLAD is playing a leading role in research on Chinese medicinal herbs, and has been working as WHO Collaborating Center for Traditional Medicine.

The Pistoia Alliance and Scilligence Announce HELM Web Editor

Boston, February 7, 2017

The Pistoia Alliance and Scilligence Corporation are pleased to announce the release of the HELM (Hierarchical Editing Language for Macromolecules) Web Editor, which brings HELM’s industry standard biomolecular representation to the browser, greatly enhancing the deployability of the technology for its adopters.

As the therapeutic utilization of complex and unique biomolecules has become commonplace in drug discovery R&D, scientists have struggled to represent these entities in their information systems, forcing them to use various “pick and mix” approaches that include multiple nomenclatures and textual descriptions. HELM, the open biomolecular representation standard, has solved this problem by providing a means to represent various types of complex macromolecules (e.g. nucleotides, proteins, antibodies and antibody-drug conjugates) including those that contain non-natural elements such as chemically modified amino acids.

The Pistoia Alliance formalized the HELM notation, originally created by Pfizer scientists as an open standard in early 2013, and publicly released the related software toolkit and editor to the Open Source community. Since its release, HELM has benefited from a growing ecosystem of global adopters and contributors including organizations such as Bristol Myers Squibb, Pfizer, Novartis, Roche, GSK, Ionis, Merck and Co, Scilligence, NextMove Software, ACD/Labs, Arxspan, BioChemfusion, Dassault Systèmes BIOVIA, ChemAxon, Perkin-Elmer, quattro research, EMBL-EBI, NCBI (PubChem), and RDKit.

While the original HELM Applet editor, supporting HELM Notation 1.0 and developed using Java, made it easier for scientists to draw and view macromolecules, technology evolved, leaving the applet unsupported by many browsers. The new HELM Web Editor is completely built on JavaScript, which removes dependencies and increases the compatibilities with modern browsers.

2017 will see further updates to the web editor to add monomer and ruleset management, support for the HELM 2.0 ambiguity features and antibody editing.

As major contributors to this project, Novartis AG and Ionis Pharmaceuticals are adopting the new HELM Web Editor.

Dr. Eric Swayze, Vice President of Chemistry and Neuroscience Drug Discovery at Ionis Pharmaceuticals adds: “The new HELM Web Editor makes it easier for our scientists to adopt the HELM technologies, which helps them to more efficiently represent and register complex chemically modified biomolecules, which facilitates exchange of information within the team.”

Dr. Jinbo Lee, CSO of Scilligence adds: “We appreciate the opportunity working on the project. The new HELM Web Editor’s zero-footprint and enhanced usability will help the scientific community including life-science, academic, and technology organizations adopt the HELM standard.”

About Pistoia Alliance
The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 80 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.
www.pistoiaalliance.org

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.
www.scilligence.com

Contact
Krystyana Roman, Marketing Specialist, Scilligence.
[email protected]
+1 (617) 520-4588

Claire Bellamy, Project Manager, Pistoia Alliance
[email protected]
+44 7823 470513

Read on Pistoia Alliance’s site

Shanghai Hengrui Pharmaceutical Co., Ltd. has licensed Scilligence ELN

January 12, 2016

Shanghai Hengrui Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Medicine Co., Ltd, has licensed Scilligence ELN (Electronic Laboratory Notebook) as a company-wide platform for their drug discovery and development effort. This State-of-the-art ELN platform will empower more efficient collaborations and knowledge management within the company and with external collaborators including CROs.


About Scilligence

Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.


About Shanghai Hengrui Pharmaceutical Co., Ltd
Shanghai Hengrui Pharmaceutical Co. Ltd. is the research and development Center of Jiangsu Hengrui Medicine Co., Ltd., which is a fully integrated pharmaceutical company in China, with annual net sales of over U.S. $1.4 billion. Hengrui is recognized as the top innovative Chinese drug company, with about 20 new molecular entities entering clinical trials and dozens more under pre-clinical development. Hengrui’s products and R&D span over multiple therapeutic areas, such as oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media, and anti-inflammation. Please visit http://www.shhrp.com and http://www.hrs.com.cn for further information.

Bio-IT World Conference

May 16-18, 2023
Hynes Convention Center, Boston, MA

Spring Informatics Webinar (Recording Available)

May 15, 2020

Scilligence held a Scilligence Spring R&D Informatics Webinar on May 15, 2023.

This webinar included exciting presentations that highlighted our work in HELM and how it has led to the development of new features. This webinar also featured presentations on Lipid Nanoparticles experimental workflow in ELN, and sharing what we’ve been working on for AI/lab automation initiatives.

Access the full recording here

AGENDA

Conjugate Builder for ADCs (Any Drug Conjugate)
Presentation by Alan Olague, Director of Sales and Marketing

Mol2HELM: Fostering ease of adoption of HELM notation
Presentation by Scotty Blechman, Manager, Software Development

Lipid Nanoparticles in ELN
Presentation by Kevin Peuler, Senior Application Scientist

Accelerate Scientific Discovery with AI-Powered Cell Counting and Labeling Inside of Scilligence ELN
Presentation by Jason Hamm, Frontend Developer

Speech Dictation in Scilligence ELN
Presentation by Sena Szczepaniuk, Scientific Software Engineer

For more information contact [email protected]

Scilligence with CAS Virtual Event (Recording Available)

January 14, 2020

Scilligence has partnered with CAS, a division of the American Chemical Society, to enable direct access to CAS scientific content through the Scilligence informatics platform. Users can now query CAS REGISTRY® directly from Scilligence ELN and Scilligence Inventory. Researchers will greatly benefit from utilizing the largest and most up-to-date collection of scientific information.

Integration with ELN and Inventory Includes:
• CAS Registry Number® to Structure
• CAS Name to Structure

Agenda:

1. Intro to Scilligence and CAS solutions
2. Current Integration: Scilligence ELN and Inventory with CAS REGISTRY
3. Demo
4. Roadmap for future integration

For more information please contact [email protected]

The Best Scientific Decision Support Platforms Part 2

October 27, 2020; 2:00pm (EST)
Virtual - RECORDING AVAILABLE

Data Analytics and Visualization Options in Registration and MS Office

October 28, 2020; 2:00-3:00pm (EST)
Virtual - RECORDING AVAILBLE

R&D Informatics for Special Modalities

October 14, 2020; 1:00-3:30pm (EST)
Virtual - RECORDING AVAILABLE

Data Analytics for Lab Informatics

September 16, 2020; 2:00-3:00pm (EST)
Virtual - RECORDING AVAILABLE